About Us
Vivesto is a Swedish drug development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential.
The project portfolio consists of Cantrixil, which is being developed for blood cancer, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma following splenectomy and in a dose-finding study in cats with solid tumors.
Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE).
-
Non Regulatory November 24, 2025Vivesto holds a live-streamed business update today November 24
-
Regulatory November 20, 2025Notice of Extraordinary General Meeting in Vivesto AB
-
Regulatory November 20, 2025Vivesto resolves on a fully secured rights issue of approximately SEK 53.8 million, subject to approval by an Extraordinary General Meeting
Interim Report Q3 2025 (in Swedish)
Vivesto published its Q3 report for 2025 on November 20, 2025, at 08.00 am CET.